Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Crowell, Valerie ^a,b   Briët, Olivier Jt ^a,b   Hardy, Diggory ^a,b   Chitnis, Nakul ^a,b   Maire, Nicolas ^a,b   Pasquale, Aurelio Di ^a,b   Smith, Thomas A ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cost; Effectiveness; falciparum; Incremental; Malaria; Mass; Screening; Treatment

Indexed keywords

ADOLESCENT; AFRICA; ARTICLE; BED NET; CASE MANAGEMENT; CHILD; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INFECTION RATE; INOCULATION; MALARIA FALCIPARUM; MASS SCREENING; MASS SCREENING AND TREATMENT; PARASITE LOAD; PARASITE TRANSMISSION; PARASITE VECTOR; PRESCHOOL CHILD; SCHOOL CHILD; SIMULATION; VECTOR CONTROL;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGED; AGED, 80 AND OVER; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; YOUNG ADULT;

EID: 84871711939     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-4     Document Type: Article

References (53)

1. Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis. Kern SE, Tiono AB, Makanga M, Gbadoe AD, Premji ZG, Gaye O, Sagara I, Ubben D, Cousin M, Oladiran F, Sander O, Ogutu B, Malar J 2011 10 210 10.1186/1475-2875-10-210 21801345
2. A research agenda for malaria eradication: drugs. The malERA Consultative Group on Drugs, PLoS Med 2011 8 1000402 21311580
3. Artemisinin resistance: current status and scenarios for containment. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L, Nat Rev Microbiol 2010 8 272 280 20208550
4. Mass administrations of antimalarial drugs. von Seidlein L, Greenwood BM, Trends Parasitol 2003 19 452 460 10.1016/j.pt.2003.08.003 14519583 (Pubitemid 38366142)
5. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basanez M, Ghani AC, PLoS Med 2010 7 1000324 10.1371/journal.pmed.1000324 20711482
6. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC, PLoS One 2011 6 20179 10.1371/journal.pone.0020179 21629651
7. Can we depend on case management to prevent re-establishment of P. falciparum malaria, after local interruption of transmission? Crowell V, Hardy D, Briet O, Chitnis N, Maire N, Smith T, Epidemics 2012 4 1 8 10.1016/j.epidem.2011.10.003 22325009
8. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). Wilson AL, PLoS One 2011 6 16976 10.1371/journal.pone.0016976 21340029
9. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C, Lancet 2009 374 1533 1542 10.1016/S0140-6736(09)61258-7 19765816
10. The role of antimalarial treatment in the elimination of malaria. Gosling RD, Okell L, Mosha J, Chandramohan D, Clin Microbiol Infect 2011 17 1617 1623 10.1111/j.1469-0691.2011.03660.x 21951597
11. The role of anti-malarial drugs in eliminating malaria. White NJ, Malar J 2008 7 Suppl 1 8 19091042
12. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, Tanner M, PLoS Med 2012 9 1001157 10.1371/journal.pmed.1001157 22272189
13. A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L, AmJTrop Med Hyg 2006 75 19 31
14. An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L, AmJTrop Med Hyg 2006 75 56 62
15. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Ross A, Maire N, Molineaux L, Smith T, AmJTrop Med Hyg 2006 75 63 73
16. A mathematical model for the dynamics of malaria in mosquitoes feeding on a heterogeneous host population. Chitnis N, Smith T, Steketee R, J Biol Dyn 2008 2 259 285 10.1080/17513750701769857 22876869
17. A periodically-forced mathematical model for the seasonal dynamics of malaria in mosquitoes. Chitnis N, Hardy D, Smith T, Bull Math Biol 2012 74 1098 1124 10.1007/s11538-011-9710-0 22218880
18. Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen J, Lyimo E, Takken W, Teuscher T, Tanner M, Acta Trop 1993 54 55 72 10.1016/0001-706X(93)90068-M 8103627 (Pubitemid 23236067)
19. Malaria Elimination Group, Malaria Elimination in Zanzibar: a Feasibility Assessment 2009
20. The use of mobile phone data for the estimation of the travel patterns and imported Plasmodium falciparum rates among Zanzibar residents. Tatem AJ, Qiu Y, Smith DL, Sabot O, Ali AS, Moonen B, Malar J 2009 8 287 10.1186/1475-2875-8- 287 20003266
21. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-Saharan Africa. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, Tanner M, AmJTrop Med Hyg 2006 75 90 103
22. Consultoria de Serviços e Pesquisas-COSEP Lda Consultoria de Gestão e Administração em Saúde-Consaúde Lda. [Angola] Macro International Inc, Angola Malaria Indicator Survey 2006-07 Calverton, Maryland: COSEP Lda., Consaúde Lda., and Macro International Inc 2007 20351775
23. Tanzania Commission for AIDS Zanzibar AIDS Commission National Bureau of Statistics Office of the Chief Government Statistician Macro International Inc, Tanzania HIV/AIDS and Malaria Indicator Survey 2007-08 Dar es Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, and Macro International Inc 2008 22649486
24. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP, AmJTrop Med Hyg 2004 71 525 530 (Pubitemid 39601144)
25. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Kokwaro G, Mwai L, Nzila A, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809 (Pubitemid 46070831)
26. Goodman C, Coleman P, Mills A, Economic analysis of malaria control in sub-Saharan Africa Geneva: Global Forum for Health Research 2000
27. Treatment seeking for malaria: a review of recent research. McCombie SC, Soc Sci Med 1996 43 933 945 10.1016/0277-9536(95)00446-7 8888463 (Pubitemid 26306536)
28. Relationships between host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Ross A, Killeen G, Smith T, AmJTrop Med Hyg 2006 75 32 37
29. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, Coleman R, Jawara M, Lindsay SW, Drakeley C, De Martin S, Olliaro P, Bennett S, Schim van der Loeff M, Okunoye K, Targett GA, McAdam KP, Doherty JF, Greenwood BM, Pinder M, Trans R Soc Trop Med Hyg 2003 97 217 225 10.1016/S0035-9203(03)90125-8 14584381 (Pubitemid 37265637)
30. INDEPTH Network, Population and Health in Developing Countries. Volume 1. Population, Health and Survival at INDEPTH Sites Ottawa, Ontario, Canada: International Development Research Centre 2002
31. National Bureau of Statistics Tanzania and ICF Macro, Tanzania Demographic and Health Survey 2010 Dar es Salaam, Tanzania: NBS and ICF Macro 2011
32. Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in The Gambia: a randomised controlled trial. Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, Conway DJ, Jasseh M, Wiseman V, Milligan PJ, Greenwood B, PLoS Med 2011 8 1000409 10.1371/journal.pmed.1000409 21304921
33. United States Department of Commerce Bureau of Economic Analysis: http://www.bea.gov/national/nipaweb/index.asp
34. Simulation of the cost-effectiveness of malaria vaccines. Tediosi F, Maire N, Penny M, Studer A, Smith TA, Malar J 2009 8 127 10.1186/1475-2875-8-127 19505328
35. The economic impact of malaria in Africa: a critical review of the evidence. Chima RI, Goodman CA, Mills A, Health Policy 2003 63 17 36 10.1016/S0168-8510(02)00036-2 12468115 (Pubitemid 35418232)
36. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S, Value Health 2005 8 521 533 10.1111/j.1524-4733.2005.00045.x 16176491 (Pubitemid 41727304)
37. Costs and cost-effectiveness of malaria control interventions-a systematic review. White MT, Conteh L, Cibulskis R, Ghani AC, Malar J 2011 10 337 10.1186/1475-2875-10-337 22050911
38. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis Geneva: World Health Organization, Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL, 2003
39. Allowing for differential timing in cost analyses: discounting and annualization. Walker D, Kumaranayake L, Health Policy Plan 2002 17 112 118 10.1093/heapol/17.1.112 11861593 (Pubitemid 34206158)
40. Partnership RBM, Global malaria action plan for a malaria-free world Geneva: Roll Back Malaria Partnership 2008
41. World Health Organization, World Malaria Report 2011 Geneva: World Health Organization 2011
42. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Shillcutt SD, Walker DG, Goodman CA, Mills AJ, PharmacoEconomics 2009 27 903 917 10.2165/10899580-000000000-00000 19888791
43. Socioeconomic aspects of neglected tropical diseases. Conteh L, Engels T, Molyneux DH, Lancet 2010 375 239 247 10.1016/S0140-6736(09)61422-7 20109925
44. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Linehan M, Hanson C, Weaver A, Baker M, Kabore A, Zoerhoff KL, Sankara D, Torres S, Ottesen EA, AmJTrop Med Hyg 2011 84 5 14 10.4269/ajtmh.2011.10-0411
45. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. Blackburn BG, Eigege A, Gotau H, Gerlong G, Miri E, Hawley WA, Mathieu E, Richards F, AmJTrop Med Hyg 2006 75 650 655 (Pubitemid 46941270)
46. National mass drug administration costs for lymphatic filariasis elimination. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, Garshong B, Gyapong J, Kabali C, Kamal HA, Kanjilal S, Kyelem D, Lizardo J, Malecela M, Mubyazi G, Nitiema PA, Ramzy RM, Streit TG, Wallace A, Brady MA, Rheingans R, Ottesen EA, Haddix AC, PLoS Negl Trop Dis 2007 1 67 10.1371/journal.pntd.0000067 17989784 (Pubitemid 352024664)
47. Malaria eradication on islands. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A, Lancet 2000 356 1560 1564 10.1016/S0140-6736(00)03127- 5 11075770
48. Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Clyde DF, Bull World Health Organ 1962 27 203 212 14021798
49. A research agenda for malaria eradication: diagnoses and diagnostics. malERA Consultative Group on Diagnoses and Diagnostics, PLoS Med 2011 8 1000396 21311583
50. Operational strategies to achieve and maintain malaria elimination. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G, Lancet 2010 376 1592 1603 10.1016/S0140-6736(10)61269-X 21035841
51. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A, PLoS One 2007 2 1311 10.1371/journal.pone.0001311 18074034 (Pubitemid 351802583)
52. Costs and consequences of large-scale vector control for malaria. Yukich JO, Lengeler C, Tediosi F, Brown N, Mulligan JA, Chavasse D, Stevens W, Justino J, Conteh L, Maharaj R, Erskine M, Mueller DH, Wiseman V, Ghebremeskel T, Zerom M, Goodman C, McGuire D, Urrutia JM, Sakho F, Hanson K, Sharp B, Malar J 2008 7 258 10.1186/1475-2875-7-258 19091114
53. Importance of factors determining the effective lifetime of a mass, long-lasting, insecticidal net distribution: a sensitivity analysis. Briet OJ, Hardy D, Smith TA, Malar J 2012 11 20 10.1186/1475-2875-11-20 22244509